Dr. Jorge Cortes, MD
Claim this profileGeorgia Cancer Center at Augusta University
Expert in T-Lymphoblastic Leukemia/Lymphoma
Studies Myeloid Leukemia
14 reported clinical trials
19 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderBCR-ABL1 positive
b2a2 (e13a2) positive
b3a2 (e14a2) positive
2Myeloid Leukemia
BCR-ABL1 positive
b2a2 (e13a2) positive
b3a2 (e14a2) positive
Affiliated Hospitals
Clinical Trials Jorge Cortes, MD is currently running
CTO1681
for Preventing Side Effects in Cancer Therapy
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed CAR T-cell therapy. The first phase of the study will be open label with dose escalation. Participants will start taking CTO1681 just prior to receiving their CAR T-cell therapy and continue to take the study drug three times daily for a total of 15 days.
Recruiting1 award Phase 1 & 2
Asciminib Combinations
for Chronic Myeloid Leukemia
This trial tests the effectiveness and safety of a medication called asciminib in patients newly diagnosed with Chronic Myeloid Leukemia in the Chronic Phase. Patients will take asciminib daily, and if they do not respond after a few years, they may also take another low-dose medication. Asciminib works by blocking a protein that helps cancer cells grow.
Recruiting1 award Phase 2
More about Jorge Cortes, MD
Clinical Trial Related6 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jorge Cortes, MD has experience with
- Asciminib
- Nilotinib
- Azacitidine
- Imatinib
- Ponatinib Hydrochloride
- FT-2102 (olutasidenib)
Breakdown of trials Jorge Cortes, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Myeloid Leukemia
Chronic Myelogenous Leukemia
Chronic Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jorge Cortes, MD specialize in?
Jorge Cortes, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Myeloid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved BCR-ABL1 positive patients, or patients who are b2a2 (e13a2) positive.
Is Jorge Cortes, MD currently recruiting for clinical trials?
Yes, Jorge Cortes, MD is currently recruiting for 4 clinical trials in Augusta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Jorge Cortes, MD has studied deeply?
Yes, Jorge Cortes, MD has studied treatments such as Asciminib, Nilotinib, Azacitidine.
What is the best way to schedule an appointment with Jorge Cortes, MD?
Apply for one of the trials that Jorge Cortes, MD is conducting.
What is the office address of Jorge Cortes, MD?
The office of Jorge Cortes, MD is located at: Georgia Cancer Center at Augusta University, Augusta, Georgia 30912 United States. This is the address for their practice at the Georgia Cancer Center at Augusta University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.